Xsensio
Xsensio is a Swiss deep-tech company developing the Lab-on-Skin™ wearable biosensing platform for continuous, real-time biochemical monitoring of proteins, hormones, ions, and metabolites from interstitial fluid, targeting hospitals, ICUs, pharmaceutical companies, and sports organizations.
- Company typePrivate
- Founded2016
- HeadquartersLausanne, Switzerland
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Xsensio does
Xsensio SA is a Swiss deep-tech company founded in 2016 as a spin-out from the Nanolab of EPFL (Swiss Federal Institute of Technology Lausanne) and headquartered at EPFL Innovation Park in Lausanne. The company develops the Lab-on-Skin™ wearable biosensing platform, an ultra-miniaturized chip that uses semiconductor-based extended-gate field-effect transistor (FET) sensing, nanotechnology, and three-dimensional passive microfluidics to continuously measure biochemical biomarkers — including proteins, hormones, ions, and metabolites — directly from interstitial fluid on the skin. The technology originated in research led by co-founder and CTO Prof. Adrian Ionescu at EPFL Nanolab, with co-founder and CEO Esmeralda Megally (MIT MBA) driving commercialization.
The product portfolio centers on the Lab-on-Skin™ sensing chip, the integrated wearable biosensing device, and the XPATCH wearable skin patch developed through a Eurostars-funded consortium with Fraunhofer IZM, OmegaLambdaTec, R-DAS, and Vrije Universiteit Amsterdam. The platform is configured as a modular, multi-sensor architecture that can be tailored for specific clinical applications including ICU organ dysfunction monitoring, oncology inflammation detection, post-surgical recovery, chronic disease management, and elite athlete performance (heat acclimatization). Long-term collaboration with Texas Instruments provides a CMOS integration pathway for scaled semiconductor manufacturing.
Xsensio operates a B2B enterprise go-to-market targeting hospitals, ICUs, pharmaceutical companies, and sports performance organizations, with revenue mechanics based on hardware sales of biosensing devices and patches plus tailored data analytics services that could convert to subscription or recurring models. Named enterprise relationships include Mayo Clinic (know-how and stock purchase agreement, MedTech Accelerator), UCB (Digital Care Transformation program), MotionLab (athlete deployment), and advisory collaboration with CHUV. The company is venture-backed, with a $7M oversubscribed Series A closed in March 2026 led by WI Harper.
Xsensio firmographics
Firmographics- Name
- Xsensio
- Legal name
- Xsensio SA
- Website
- https://xsensio.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Xsensio is a Swiss deep-tech company developing the Lab-on-Skin™ wearable biosensing platform for continuous, real-time biochemical monitoring of proteins, hormones, ions, and metabolites from interstitial fluid, targeting hospitals, ICUs, pharmaceutical companies, and sports organizations.
- Ownership category
- akta.pro rank
Xsensio industry classification
Industry- Product category
- Wearable Biosensing Devices
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
- SIC
- Laboratory Analytical Instruments (3826), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Biosensors & Lab-on-Chip (BioMEMS) (HDAHALAK)
- akta.pro secondary industry
- Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)
Keywords
Where Xsensio is headquartered
LocationHeadquarters
- HQ city
- Lausanne
- HQ country
- Switzerland
- HQ region
- Europe
Offices1 record
Markets served
Xsensio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Revenue model
- Lab-on-Skin™ Wearable Biosensing Platform: Sale of wearable biosensing devices and patches for continuous health monitoring in clinical settings, hospitals, and home care environments.
- Data Analytics and Software Services: Tailored data analytics tools to convert raw sensor data into actionable insights for clinical decision-making, potentially sold as subscription or service model.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels8 records
Xsensio product offering
Product offeringCore offering
Xsensio develops the Lab-on-Skin™ sensing platform, an ultra-miniaturized wearable biosensing chip that uses semiconductor-based extended gate field-effect transistor (FET) technology and 3D microfluidics to continuously monitor biochemical biomarkers (proteins, hormones, ions, metabolites) from interstitial fluid. The modular, configurable platform is designed for clinical applications including ICU early detection of organ dysfunction, oncology inflammation monitoring, and post-surgical recovery, with accompanying data analytics tools that convert raw sensor readings into actionable clinical insights.
Product overview
Xsensio develops the Lab-on-Skin™ sensing platform, a wearable biosensing technology consisting of an ultra-miniaturized sensing chip, proprietary skin interface, and wireless communication module. The platform enables continuous real-time monitoring of biochemical biomarkers including proteins, hormones, ions, and metabolites from interstitial fluid. The core Lab-on-Skin™ device integrates a customized multi-sensor chip configurable for specific clinical applications such as ICU shock monitoring, inflammation detection in oncology, and post-surgical recovery. Data analytics tools are developed for each application to convert raw sensor data into actionable insights. Xsensio also developed the XPATCH wearable skin patch through a Eurostars-funded consortium project for expanded biomarker detection capabilities.
Differentiator
Problem solved
Functional benefit
Products and services
- Lab-on-Skin™ Sensing Platform A wearable biosensing platform that enables continuous, real-time monitoring of biochemical biomarkers (proteins, hormones, ions, metabolites) from interstitial fluid on the skin, leveraging semiconductor technology for miniaturization and high sensitivity. Targeted at hospitals, ICU settings, and home care for clinical decision-making.
- Lab-on-Skin™ Wearable Biosensing Device Wearable device enabling simultaneous, continuous monitoring of multiple biochemical biomarkers for clinical decision-making, featuring an ultra-miniaturized chip with customizable multi-sensor configuration for application-specific clinical use cases.
- Lab-on-Skin™ Sensing Chip
Quantifiable outcome
- Earlier detection of organ dysfunction and clinical deterioration in ICU, outpatient, and home settings
- +1 more outcomes
Companies that use Xsensio
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles3 records
Xsensio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Xsensio partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core, major and minor.
- Texas InstrumentscoreLong-term collaboration with Texas Instruments to leverage semiconductor expertise in CMOS integration, miniaturization, and large-scale manufacturability of biosensing systems. CTO of Texas Instruments visited Xsensio to discuss future of biosensing. Collaboration strengthens industrial scalability and advanced semiconductor technology integration.
- Mayo CliniccoreKnow-how and stock purchase agreement with Mayo Clinic for development of new wearable products based on short-term health dynamics in critical care. Mayo Clinic provides clinical and product development expertise. Dr. Ayan Sen serves on Xsensio Board of Advisors.
- Mayo Clinic / ASU MedTech AcceleratormajorSelected by Mayo Clinic and Arizona State University to participate in world-class MedTech Accelerator program in US. Common goal: advance value-based healthcare through continuous monitoring.
- UCBmajorIntegrated into UCB Digital Care Transformation (DCTx) program along with 3 other companies. Focus on innovation along patient journey and potential impact on individual lives of patients.
- MotionLabmajorStrategic collaboration with MotionLab, a renowned sport performance center training top athletes. First deployment of Lab-On-Skin patches at MotionLab for heat acclimatization studies targeting Tokyo and Doha competitions.
- PhilipsminorXsensio part of EIC cohort of nine startups taking part in virtual Corporate Day with Philips medtech corporate.
- EPFL NanolabcoreSpin-out from EPFL Nanolab where core Lab-on-Skin technology was developed. Prof. Adrian Ionescu is co-founder and CTO, leading the Nanolab. Technology leverages semiconductor properties from this research.
- Eurostars XPATCH Consortium Partners (Fraunhofer IZM, OmegaLambdaTec, R-DAS, Vrije Universiteit Amsterdam)minor€2.4M XPATCH project consortium funded by Eurostars to develop next-generation wearable skin patch for ultrasensitive real-time health monitoring. Four European partners collaborating on sensors, flexible battery, and clinical testing.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
Xsensio competitors and assessment
Company assessmentDirect peers
- Abionic: Swiss EPFL-area nanofluidic biosensing platform (abioSCOPE) for rapid point-of-care diagnostics including allergy and inflammation panels. Closest peer by technology origin, geography, and stage.
- Epicore Biosystems: US-based developer of sweat-sensing wearable patches for hydration, stress, and metabolic biomarkers. Directly comparable as a wearable biochemical sensor platform pursuing continuous monitoring use cases.
- Biolinq: Developer of an intradermal biosensor patch with multiple electrochemical sensors for continuous metabolic monitoring. Comparable as a multi-analyte wearable biochemical sensor targeting similar clinical and wellness use cases.
Broad incumbents
- Dexcom: Leader in continuous glucose monitoring (CGM) with established hospital and consumer channels. Comparable as the dominant incumbent defining the continuous-biosensor category Xsensio seeks to expand beyond glucose.
- Abbott (Diabetes Care / FreeStyle Libre): Global leader in flash and continuous glucose monitoring via interstitial fluid sensing (FreeStyle Libre). Highly comparable continuous ISF biosensor incumbent with established scale, regulatory, and clinical infrastructure.
Emerging players
- Senseonics (Eversense): Implantable continuous glucose monitoring system (Eversense) using a long-term subcutaneous sensor. Comparable as a continuous biochemical monitoring company pursuing alternate form factors and clinical settings.
- Nutromics: Australian developer of a DNA-based wearable patch for continuous multi-analyte diagnostics. Comparable as an early-stage multi-biomarker wearable biosensor targeting clinical and pharmaceutical applications.
- Movano Health: Developer of wearable devices for continuous health metrics, including a cuffless blood pressure and glucose monitor in development. Comparable as a continuous-monitoring wearable healthtech company pursuing multiple biomarkers.
- Kenzen: Developer of a sweat-based wearable patch for continuous physiological and biochemical monitoring, primarily targeting worker safety and athletic performance. Comparable as a wearable biochemical monitoring platform.
Others
- Owlstone Medical: Developer of breath-based diagnostics for disease detection and biomarker monitoring. Thematically adjacent as a non-invasive continuous biomarker company, though using a different sensing modality.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Xsensio social profiles
Digital presenceXsensio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Xsensio leadership team
Management profileNumber of profiles
Profiles13 records
Xsensio funding detail
Funding detailFunding overview
Funding rounds13 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Xsensio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Xsensio
What does Xsensio do?
Xsensio develops the Lab-on-Skin™ sensing platform, an ultra-miniaturized wearable biosensing chip that uses semiconductor-based extended gate field-effect transistor (FET) technology and 3D microfluidics to continuously monitor biochemical biomarkers (proteins, hormones, ions, metabolites) from interstitial fluid. The modular, configurable platform is designed for clinical applications including ICU early detection of organ dysfunction, oncology inflammation monitoring, and post-surgical recovery, with accompanying data analytics tools that convert raw sensor readings into actionable clinical insights.
Is Xsensio a public or private company?
Xsensio is a private company. It is classified as venture growth investor backed and is currently operating.
When was Xsensio founded?
Xsensio was founded in 2016. It employs 11 to 50 people.
Where is Xsensio based?
Xsensio is headquartered in Lausanne, Switzerland, in the Europe region.
How does Xsensio make money?
Two revenue lines are on record. Lab-on-Skin™ Wearable Biosensing Platform is the primary driver. The others are data Analytics and Software Services.
Who are Xsensio's main competitors?
Direct peers on record are Abionic, Epicore Biosystems and Biolinq. Broad incumbents are Dexcom and Abbott (Diabetes Care / FreeStyle Libre). Emerging players are Senseonics (Eversense), Nutromics, Movano Health and Kenzen. Owlstone Medical is listed as an others.
Does Xsensio have an API?
No public API is recorded for Xsensio.
What industry is Xsensio in?
Xsensio's product category is Wearable Biosensing Devices. Its primary akta.pro industry code is HDAHALAK, Biosensors & Lab-on-Chip (BioMEMS), with a secondary code of HLACAFAL, Connected Therapeutics & Smart Drug Delivery Monitoring. Its NAICS code is 334516 and its SIC code is 3826.